Safety and immunogenicity of human papillomavirus-16/18 AS04-adjuvanted vaccine in healthy Chinese females aged 15 to 45 years:a phase Ⅰ trial

Globally,about 70% of cervical cancers are associated with human papillomavirus (HPV)-16 or HPV-18 infection.A meta-analysis of epidemiologic studies in China showed that HPV was present in 98% of cervical cancer samples.The HPV-16/18 AS04-adjuvanted vaccine Cervarix has shown a high level of protection against HPV-16/18 infections and associated cervical lesions.This phase Ⅰ trial (NCT00549900) assessed the safety,tolerability,and immunogenicity of the vaccine in Chinese.Thirty healthy Chinese females,aged 15 to 45 years with a median age of 29.5 years,received three doses of Cervarix in Months 0,1,and 6.Safety was assessed via recording solicited local and systemic symptoms within 7 days and unsolicited symptoms within 30 days after each vaccination.Serious adverse events,new onset of chronic diseases,and other medically significant conditions were recorded throughout this trial.As an exploratory objective,HPV-16/18 antibody titers were determined by enzyme-linked immunosorbent assay in serum samples collected in Months 0 and 7.Pain at the injection site was the most frequently reported local symptom.Two subjects reported medically significant adverse events.Both cases were assessed as unrelated to vaccination by the investigator.In Month 7,100% seroconversion was observed for both anti-HPV-16 and anti-HPV-18 with high geometric mean antibody titers.HPV-16/18 AS04-adjuvanted vaccine,evaluated for the first time in Chinese females,was generally well tolerated and immunogenic,as previously shown in global studies.

HPV16E7-HSP70 Hybrid DNA Vaccine Induces E7-Specific Cytotoxic T Cells and Antitumor Immunity

Using human papillomavirus type 16 （HPV16） E7 as an antigen and Heat Shock Protein 70 as adjuvant, we constructed a DNA vaccine by linking HSP70 gene to E7^C91G; gene. Mice, after being immunized with E7^C91G;-HSP70, E7^C91G/HSP70, E7^C91G, and wild E7 DNA vaccines respectively, produced E7 specific CD8^＋ T-cell precursor frequencies of 280.33±2.52, 144.34±4.04, 164.34±5.13 and 82.33±3.51 respectively within every 1 × 10^5 mouse splenocytes. This proves that E7^C91G-HSP70 fusion vaccine can significantly enhance the E7 specific cellular immunity within the mice body（p〈0. 01）. After being immunized with E7^C91G-HSP70 fusion vaccine, tumor-bearing mice of the group being treated have significantly longer latency and survival periods, comparing with other three categories of E7 vaccines. Experiment shows that this vaccine has a significant effect on enhancing E7 positive tumor-treatment within mice body. After being immunized with E7^C91G-HSP70 vaccine, there were no pathological changes found in livers, kidneys and spleens of the mice, which proves that the vaccine is quite safe. After all, E7^C91G-HSP70 fusion vaccine has a much stronger tumor- treatment effect than thai of wild type E7 DNA vaccine.

亚洲人群HPV疫苗免疫原性及安全性的Meta分析

目的评估人乳头状瘤病毒(HPV)疫苗在亚洲人群中接种后的免疫原性和安全性。方法本研究分别检索英文数据库(PubMed、Embase、Web of Science、Clinical Trails、Cochrane library)和中文数据库(中国知网、万方、维普),自建库至2022年4月,关于亚洲人群进行的HPV疫苗安全性和免疫原性临床试验文献。采用主题词与自由词灵活搭配检索并结合纳排标准筛选文献,对最终纳入文献进行质量评价并提取资料,应用Meta分析合并评估。结果最终纳入16篇随机对照试验(RCT)研究,累计研究对象25485人。Meta分析表明对于HPV疫苗免疫原性,HPV16型特异性血清转化率合并效应值RR为43.74(16.51~115.85),HPV18型特异性血清转化率合并效应值RR为45.72(8.78~238.13)。对于HPV疫苗安全性,二价与四价HPV疫苗接种局部不良事件风险试验组高于对照组,RR为1.52(1.34~1.73)和1.38(1.20~1.59)。二价HPV疫苗与四价HPV疫苗试验组发生全身性不良事件的风险也高于对照组,RR分别为1.21(1.11~1.32)和1.13(0.99~1.30)。结论接种亚洲人群HPV疫苗后血清抗体阳转率高于未接种者,提示接种HPV疫苗可以提高个体特异性抗体水平,接种HPV疫苗发生局部和全身性安全事件的风险均高于对照组,提示仍要高度重视HPV疫苗的安全性问题。

The Relationship between Human Papillomavirus and Oesophageal Squamous Cell Carcinoma in China—A Review of the Evidence

Background: China has one of the highest incidence rates of oesophageal cancer in the world. The role of human papillomavirus (HPV) has been extensively researched in oesophageal squamous cell carcinoma (OSCC) with indeterminate results. The majority of these studies have been conducted in the Chinese population. Evidence for a definitive HPV-OSCC association could potentially support prophylactic vaccination in target populations, highlighting the need for ongoing investigation. The aim of this review is to summarise the findings of HPV DNA in OSCC tissue in Chinese subjects, with a view to informing further research in this area. Methods: A systematic literature search of the Chinese National Knowledge Infrastructure (CNKI) database, Medline, Embase and PubMed was conducted for all studies in English and Chinese language, examining OSCC tissue for HPV DNA in China. Reference lists of retrieved articles were reviewed and hand searches of relevant, key journals were conducted, to source articles which were not electronically indexed. Sixty-four studies met our selection criteria. Data from case-control and cross-sectional studies were analysed separately for any HPV-OSCC association, using the Epi InfoTM 3.5.3 software program. Results: From all studies conducted in the Chinese population, 2166/5953 (36%) of all OSCC tissue and 478/1684 (28%) of healthy control tissue, tested positive for HPV. We found that 11/16 case-control and cross-sectional studies had a statistically significant crude odds ratio, which supported a potential HPV-OSCC association. The largest study, carried out in the high incidence County of Anyang in Henan Province, reported 207/265 (78%) OSCC tissues testing positive for HPV DNA against 203/357 (57%) controls and had an unadjusted odds ratio of 2.71 (p-value Conclusion: A rigorous meta-analysis would improve interpretation of the data and a well-designed large-scale case-control study is warranted. If a link is found between HPV and OSCC, prophylactic HPV vaccines could be of significant benefit in China.

Evaluation of Awareness of Human Papillomavirus and Cervical Cancer among Female Undergraduates of a Private Mission University in Southwestern Nigeria

Background: Human papillomavirus infection is most prevalent in the younger population and causes cervical cancer, which is the leading cause of cancer death worldwide. In 2018, cervical cancer was estimated to be 570,000 cases and 311,000 deaths;it ranked as the fourth most commonly diagnosed cancer and the fourth leading cause of cancer death in women. Cervical cancer can be prevented through health education and vaccination against HPV. This study aimed at evaluating the level of awareness of human papillomavirus and cervical cancer among female undergraduate students of Babcock University, Ogun state of Nigeria. Methodology: This was a cross-sectional, questionnaire-based study conducted among 310 female undergraduates of Babcock University in Nigeria from January to April 2019. The selection technique was a multistage random sampling method. The data collection was done using structured and self-administered questionnaires. Data collected were analyzed using IBM Statistical Package for Social Sciences (SPSS) statistics for windows version 25 and were presented in summary charts and frequency tables. P-values less than or equal to 0.05 were considered statistically significant. Results: Of 310 female students, 296 (95.5%) were aware of HPV infections. The majority, 215 (69.4%) of the students knew that HPV is sexually transmitted. There was poor knowledge of the risk factors of HPV infection. Only, 65 (21.0%) were aware that HPV infection causes cervical cancer. A few proportions of students 79 (25.4%) were aware of the HPV vaccine. Consequently, only 44 (14.2%) have received HPV vaccination and some complained about the cost as a significant reason for not being vaccinated against HPV infection. Conclusion: The level of awareness of HPV infection, cervical cancer, and HPV vaccine uptake was very low in this study. There is a need to improve health education and awareness campaigns among students about HPV infection, cervical cancer, and HPV vaccine uptake.

口腔HPV感染的研究现状

流行病学证据表明口腔是人乳头瘤病毒(human papillomaviruses,HPV)的储存库,水平传播和垂直传播等多种途径促进了口腔HPV感染的流行。低危型HPV感染可能导致口腔黏膜良性病变,而高危型HPV的持续感染是诱发头颈部鳞状细胞癌的重要危险因素。目前,我国关于口腔HPV感染的研究工作并不深入,国人对相关知识的认知不足,这不利于相关疾病防治工作的开展。在此背景下,本文对口腔HPV感染的研究现状进行综述,以期为我国口腔HPV感染的防治工作提供参考。

HPV感染的慢病管理

目前HPV的感染在全球人群中普遍存在,并且HPV感染人体后很难被彻底清除,因此由HPV感染所诱发的多种慢性疾病如病毒疣、宫颈上皮内瘤变、呼吸道乳头状瘤等往往存在着很高的复发率,给患者乃至社会均带来了沉重负担。因此,需要对HPV感染所诱发的慢性疾病进行科学规范的管理,进而降低HPV感染率与疾病复发率、缩短病程,从而有效促进HPV的防治工作。本文就HPV感染的慢病管理的必要性、具体方法及其意义进行综述。

Head-to-head comparison of 7 high-sensitive human papillomavirus nucleic acid detection technologies with the SPF10 LiPA-25 system

Background:The SPF10 LiPA-25 system for human papillomavirus(HPV)detection with high analytical perfor-mance is widely used in HPV vaccine clinical trials.To develop and evaluate more valent HPV vaccines,other comparable methods with simpler operations are needed.Methods:The performance of the LiPA-25 against that of other 7 assays,including 4 systems based on reverse hybridization(Bohui-24,Yaneng-23,Tellgen-27,and Hybribio-16)and 3 real-time polymerase chain reaction(PCR)assays(Hybribio-23,Bioperfectus-21,and Sansure-26),was evaluated in selected 1726 cervical swab and 56 biopsy samples.A total of 15 HPV genotypes(HPV 6,11,16,18,31,33,35,39,45,51,52,56,58,59,and 66)were considered for comparison for each HPV type.Results:Among the swab samples,compared to LiPA-25,compatible genotypes were observed in 94.1%of samples for Hybribio-23,92.8%for Yaneng-23,92.6%for Bioperfectus-21,92.4%for Hybribio-16,91.3%for Sansure-26,89.7%for Bohui-24,and 88.0%for Tellgen-27.The highest overall agreement of the 15 HPV genotypes combined was noted for Hybribio-23(κ=0.879,McNemar’s test:P=0.136),followed closely by Hybribio-16(κ=0.877,P<0.001),Yaneng-23(κ=0.871,P<0.001),Bioperfectus-21(κ=0.848,P<0.001),Bohui-24(κ=0.847,P<0.001),Tellgen-27(κ=0.831,P<0.001),and Sansure-26(κ=0.826,P<0.001).Additionally,these systems were also highly consistent with LiPA-25 for biopsy specimens(all,κ>0.897).Conclusions:The levels of agreement for the detection of 15 HPV types between other 7 assays and LiPA-25 were all good,and Hybribio-23 was most comparable to LiPA-25.The testing operation of HPV genotyping should also be considered for vaccine and epidemiological studies.

西安非医学专业女大学生对HPV和HPV疫苗的认知

目的了解西安市高校非医学专业女大学生对人乳头瘤病毒（HPV）的认知情况及其对接种HPV疫苗的态度,为制定针对非医学专业大学生健康教育模式,推广HPV疫苗的接种提供依据。方法采用整群随机抽样的方法,在西安市6所非医学类本科高校中抽取16个专业的大学二、三年级女大学生共2 131名,用自行设计的问卷进行调查,获有效问卷2 096份,有效回收率为98.4%。结果仅11.3%被调查者知晓HPV,有性生活组大学生对HPV知晓率显著高于无性生活组（χ2=20.182,P〈0.05）,来自单亲或重组家庭的女大学生对HPV知晓率显著高于来自原生家庭组（χ2=4.329,P〈0.05）。不同年级间（χ2=0.921）,来自城市或农村（χ2=0.891）,是否独生子女（χ2=0.330）组间对HPV知晓率差异无统计学意义（P〉0.05）。仅9.7%被调查者知晓HPV疫苗。79.9%的被调查者表示愿意接种HPV疫苗;担心会感染HPV（44.1%）或患宫颈癌（19.3%）的被调查者有较强的接种意愿;公众健康教育（42.2%）及医务人员推荐（34.7%）是女大学生们更愿意接受的疫苗推荐方式。超过半数被调查者（50.1%）能够接受的疫苗价格在50~100元。结论西安非医学专业大学生对HPV及HPV疫苗的知晓率低,但接种意愿强。应加强科普健康教育,普及宫颈癌一级预防、HPV及HPV疫苗相关知识。

北京市初中生家长及大学生对HPV及其预防性疫苗认知的研究

目的调查北京市初中生家长及大学生对人乳头瘤病毒（HPV）及其预防性疫苗的认知情况和接种态度。方法采用便利抽样的方法，选择北京两所普通大学及两所普通初中，用多阶段抽样方法，得到大学生和初中生家长的样本，对自填式问卷调查进行分析。结果被调查者中大多数人67．80％（537／792）听说过子宫颈癌；仅有15．91％（126／792）的人听说过HPV，其中40．48％（51／126）的人认为HPV感染后可能会导致子宫颈癌。有11．36％（90／792）的人听说过HPV疫苗；初中生家长和大学生在知道HPV疫苗可有效预防宫颈癌知晓率方面比较差异有统计学意义（X2=7．541，P〈0．01）。被调查的409名大学生中，有234人愿意接种HPV疫苗，占总人数的57．21％；被调查的383名初中生家长中，271人（70．76％）愿意接种疫苗，164人（42．82％）愿意让其孩子接种疫苗。家长性别对是否愿意让孩子接种疫苗有明显的影响（X2=10．742，P=0．001）。结论北京市初中生家长及大学生对HPV及HPV预防性疫苗认知率较低，但对HPV疫苗的接种总体上持积极支持的态度。

人乳头状病毒(HPV)与口咽癌相关性的研究进展

近年来,研究表明口腔癌的发病率总体呈下降趋势,但口咽癌的发病率却有显著增长的趋势,而且越来越多的研究表明人乳头状病毒(human papilloma virus,HPV)在口咽癌的发病及临床诊断、预后及防治中均扮演着重要的角色,使得HPV阳性的口咽癌呈现出与HPV阴性口咽癌不同的特征,这在国内外科研中受到广泛的关注。本文将对HPV与口咽癌的相关性研究的进展作一综述。

HPV 16L1基因的原核表达及表达条件的优化

目的:构建HPV16L1基因的原核表达质粒,并优化其表达条件。方法:根据GeneBank中的HPV序列及pGEX-KG中的多克隆位点设计引物,以含有HPV全长基因片段重组质粒为模板,经PCR扩增出1 500 bp的DNA片段。将所得片段与pGEX-KG载体连接,转化JM109大肠杆菌,筛选阳性克隆。其扩增片段测序结果与原序列一致,表明原核表达载体pGEX-KG-HPV16L1已构建成功。提取pGEX-KG-HPV16L1质粒转化到BL21(DE3)表达菌株中,经IPTG诱导后收集菌体,进行SDS-PAGE,Western Blot鉴定。结果:在大肠杆菌中获得HPV16L1基因融合表达,融合蛋白的相对分子量为83kDa;表达的蛋白能与抗HPV16L1抗体发生特异性反应。结论:HPV16L1基因在大肠杆菌中获得高效表达,为HPV16L1疫苗的研制奠定了基础。

HPV疫苗接种对HPV感染患者心理及生活质量的影响

目的探讨HPV感染患者在接种HPV疫苗后心理状况及生活质量的改变。方法选取2018年5月在深圳市南山区妇幼保健院确诊为HPV阳性的女性患者100例作为研究对象,其中接种HPV疫苗的50例为观察组,未接种HPV疫苗的50例为对照组。在接种前和接种完成后1周对两组患者的焦虑、抑郁情绪和生活质量进行评价分析。结果接种完HPV疫苗后,观察组的焦虑评分、抑郁评分均低于对照组,差异均有统计学意义(t值分别为4.20、3.65,均P<0.01);生活质量评分中6个维度(生理机能、躯体疼痛、一般健康、精力、社会功能、精神健康)观察组评分均高于对照组,差异均有统计学意义(t值分别为5.12、2.48、5.92、2.04、4.01、4.97,均P<0.05);观察组接种前后焦虑、抑郁评分及生活质量评分中7个维度(生理机能、躯体疼痛、一般健康、精力、社会功能、情感职能、精神健康)评分比较差异均有统计学意义(t值分别为4.05、3.54、5.23、4.74、5.99、6.95、6.89、1.97、4.86,均P<0.05)。结论HPV感染的患者及时接种HPV疫苗能有效改善患者的焦虑抑郁情绪,提高其生活质量。

HPV L2肽段宫颈癌疫苗的研究进展

在全世界范围内,宫颈癌是女性的高发肿瘤,死亡率极高,人乳头瘤病毒是其主要的致病因子。关于宫颈癌的人乳头瘤病毒疫苗研究为宫颈癌的防治带来了曙光。目前已上市的人乳头瘤病毒疫苗虽已取得一定的临床疗效,但仍然存在着许多不足,其中,仅能抑制少数高危型人乳头瘤病毒感染是最主要的缺陷之一。人乳头瘤病毒次要衣壳蛋白L2与宫颈癌的关系密切,同时L2肽段在所有人乳头瘤病毒型别均有表达,虽然免疫原性较弱,但具有很强的序列保守性,可交叉免疫多种型别的人乳头瘤病毒感染。由其构建的以人乳头瘤病毒L2肽段为基础的集预防与治疗为一体的疫苗有着极大的优越性和潜力,但也存在着不足之处,目前该方面的相关研究已在国内外逐渐展开起来,并取得了一定的进展。该文就人乳头瘤病毒次要衣壳蛋白L2与宫颈癌的关系及其构建人乳头瘤病毒疫苗的研究进展作以系统的回顾。

南平市女性HPV感染特征调查分析

目的观察南平市部分地区女性感染人乳头状病毒(HPV)情况及其与宫颈病变的关系,为宫颈癌的筛查和防治提供流行病学资料。方法收集南平市2928例妇科患者的基本资料,采集宫颈脱落细胞,采用凯普导流杂交技术行HPV亚型分型检测,分析HPV感染情况及其亚型分布并进行统计学分析。结果2928例患者中共检出HPV阳性者663例(22.64%);南平部分地区HPV阳性检出率高于全国常模、全国常模(农村)、厦门地区及福州地区(P<0.05),低于建阳地区和三明地区(P<0.05);≥61岁女性在该地区各年龄段中阳性检出率最高,第二高峰出现在21~30岁,HPV亚型多重感染主要分布在21~40岁;在HPV亚型感染中,52、16和58型是常见的HPV高危亚型。结论南平市部分地区女性HPV阳性检出率与其他地区比较,存在一定地域性差异。≥61岁和21~30岁女性是筛查HPV感染和子宫颈病变的重点人群,侧重关注当地女性宫颈鳞癌和腺癌的早期筛查和防治。加强青少年女性防护,根据年龄差异和易感类型针对性选择合适的预防性疫苗。

HPV检测和免疫治疗进展

人乳头瘤病毒(HPV)感染引起的疾病包括良性增生性疾病、宫颈癌、头颈与直肠恶性肿瘤。全球发病率居高不下,不仅影响健康也造成很大经济负担。快速、可靠和有效的HPV检测对疾病诊断和预防非常重要。目前检测方法包括聚合酶链反应(PCR),DNA原位杂交、杂交捕捉法HC-2、高危HPV感染相关生物学标记的免疫组织化学检测、以及高危型HPV E6/E7 mRNA检测等。HPV病毒蛋白免疫组化以及DNA/RNA微阵列或芯片技术在HPV检测中的应用价值非常大但尚未推广普及。对HPV免疫学机制和致癌机制的最新研究促进了HPV相关肿瘤免疫治疗的研究。预防性HPV疫苗不能诱导细胞免疫清除HPV感染、尤其无法治疗HPV相关肿瘤,故迫切需要寻求治疗HPV感染和相关肿瘤的有效手段。已经研发的几种类型治疗性疫苗,包括活载体、蛋白质或肽、核酸和基于细胞的疫苗已在进行临床前和临床试验研究。另外一些新的免疫治疗策略,如免疫检查点抑制剂、过继性T细胞疗法等仅在临床前评估阶段。

高危型HPV DNA整合导致宫颈癌的作用机制和临床检测进展

高危型人乳头瘤病毒(human papillomavirus,HPV)感染是宫颈癌发生发展的必要因素之一。病毒DNA整合到宿主基因组中被认为是导致宫颈癌最重要的病因。高危型HPV DNA整合往往导致其E1和E2区大部分缺失或中断,E6和E7致癌基因过表达,宿主致癌基因激活和抑癌基因失活。目前研究表明高危型HPV整合可作为优质宫颈病变筛查的预测生物标志物,且其检测的有效方法大都基于荧光原位杂交、实时荧光定量PCR和杂交捕获技术结合Sanger测序法等。本文重点阐述了高危型HPV整合导致宫颈癌的主要机制,描述了宫颈病变筛查标志物以及预防性HPV疫苗研发和推广的研究进展,并综述了高危型HPV DNA整合状态的检测方法。

不同人群对人乳头瘤病毒及HPV疫苗的知信行调查研究

目的分析太原市不同人群对人乳头瘤病毒(Human papillomavirus,HPV)及HPV疫苗的知信行现状及接种意愿的影响因素。方法采用多阶段随机抽样在太原市选取高中生及以上且不超过65岁、有独立认知能力的对象共988人,通过自填式问卷了解公众对HPV及其疫苗的知信行现状,接种意愿的多因素分析采用Logistic回归分析。结果公众对HPV及其疫苗相关认知较低,各条目回答正确率大多低于50.00%;态度较为积极但HPV疫苗接种率仅占4.15%,其中仅有一名男性在国外完成HPV疫苗接种;公众的认知得分情况影响其对HPV疫苗的态度(F=28.13,P<0.05);年龄(OR=3.320,P<0.05)、是否发生性行为(OR=1.836,P<0.05)、是否听说过HPV疫苗(OR=1.545,P<0.05)及态度得分(OR=1.201,P<0.05)影响人群自我接种意愿;不了解HPV疫苗(61.67%)、担心安全有效性(54.63%)和疫苗价格过高(41.41%)是影响公众不愿接种HPV疫苗的主要原因。结论人群接种HPV疫苗的意愿积极但实际接种率较低,建议增强HPV疫苗宣传的同时予以价格调控,并考虑将适龄男性纳入疫苗接种范围的必要性。

合肥地区2558例体检女性HPV感染及亚型分布情况

目的分析合肥地区常规体检女性的人乳头瘤病毒(HPV)感染及亚型分布情况。方法在Luminex 200平台上,用透景27型HPV分型试剂盒对2 558例常规体检女性的宫颈脱落细胞进行HPV基因型检测,按照年龄段分类统计数据,计算感染的阳性率,同时统计其亚型分布特点。结果HPV阳性者397例,阳性率15. 52%。样本被分为4个年龄段组:21～30岁组、31～40岁组、41～50岁组、> 50岁组,阳性率分别为13. 85%、14. 01%、16. 39%和17. 16%;高危型HPV例数与低危型HPV例数的阳性率分别为13. 02%和6. 61%。χ2检验的结果显示,各年龄段之间,总阳性率(χ2=3. 624,P=0. 305)、高危型例数的阳性率(χ2=1. 975,P=0. 578)和低危型例数的阳性率(χ2=4. 507,P=0. 212)差异无统计学意义。各年龄段单一感染率均高于多重感染率。高危型中HPV检出率较高的型别是52 (9. 76%)、16(9. 16%)、58 (6. 77%)、53 (5. 98%),低危型中HPV检出率较高的型别是61 (6. 77%)、81 (5. 78%)、55(5. 38%)。结论合肥地区女性HPV感染的年龄段和型别分布均有不同于其他地区的基因型分布情况,建议本地区人群接种含52、16、58、53型的九价HPV疫苗。

昆明地区6 091名女性HPV筛查结果及基因分型初步探讨

目的 调查昆明地区女性HPV感染情况、亚型分布、感染年龄分布。方法 利用流式荧光杂交法,对2021年于昆明市妇幼保健院进行就诊的6 091名女性宫颈脱落细胞进行HPV基因型检测,分类统计后得出感染率、基因亚型、年龄分布情况。结果 HPV感染人数1 301例,感染率21.36%。单一感染者占多数(78.94%)。所有阳性标本中,高危型感染例数较低危型感染例数多。感染率最高的分别为HPV52型(21.83%)、HPV16型(11.38%)、HPV58型(10.76%)。将参检者按年龄分为≤20岁组、21~30岁组、31~40岁组、41~50岁组、51~60岁组、> 60岁组。> 60岁组HPV感染率最高,其次为21~30岁组、51~60岁组。结论 昆明地区女性HPV感染情况以高危型为主,高龄和30岁以下人群需加强防治宣传教育,建议适龄女性尽早接种多价宫颈癌疫苗。